CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Biogen Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Biogen Inc
225 Binney Street
Phone: (781) 464-2000p:781 464-2000 CAMBRIDGE, MA  02142  United States Ticker: BIIBBIIB
Business Summary
Biogen Inc. is a global biopharmaceutical company focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. It has a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). It is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. The Company’s marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS; and FUMADERM for the treatment of severe plaque psoriasis. It also has collaborations for the commercialization of LEQEMBI, ZURZUVAE, RITUXAN, RITUXAN HYCELA, GAZYVA, OCREVUS, LUNSUMIO, and COLUMVI. It commercializes a portfolio of biosimilars of advanced biologics including BENEPALI, IMRALDI, FLIXABI, and BYOOVIZ.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-YesYes--

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202412/31/2023YesYes--Yes

Industries
SIC Code Description
2836 Biological products, except diagnostic substances
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board Caroline D.Dorsa 64 6/14/2023 1/3/2010
President, Chief Executive Officer, Director Christopher A.Viehbacher 64 11/14/2022 11/14/2022
Chief Financial Officer, Executive Vice President Michael R.McDonnell 60 8/15/2020 8/15/2020
12 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Human Immunology Biosciences, Inc. 6000 Shoreline Ct South San Francisco CA United States
Nightstar Therapeutics PLC 9-10 Midford Place LONDON MA United Kingdom
Reata Pharmaceuticals Inc 5320 Legacy Dr PLANO TX United States

Business Names
Business Name
BIIB
BIIB Colombia S.A.S.
Biogen (Argentina) SRL
96 additional Business Names available in full report.

General Information
Number of Employees: 7,570 (As of 12/31/2023)
Outstanding Shares: 145,719,340 (As of 10/29/2024)
Shareholders: 420
Stock Exchange: NASD
Federal Tax Id: 330112644
Fax Number: (302) 636-5454
Email Address: idecir@idecpharm.com


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, November 20, 2024